Dossier assessment
Inebilizumab (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Inebilizumab (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Inebilizumab (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V
Drug assessment at a glance
-
Drug assessment at a glance
Inebilizumab (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with generalized myasthenia gravis for whom add-on therapy to standard treatment is an option
- Patients with anti-AChR antibody-positive generalized myasthenia gravis: added benefit not proven
- Patients with anti-MuSK antibody-positive generalized myasthenia gravis: added benefit not proven
Project details
- Project no.
- A26-27
- Commission
- Commission awarded on 12.03.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
- https://doi.org/10.60584/A26-27
Connected Projects
-
Dossier assessment
Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Inebilizumab (immunoglobulin G4-related disease) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed